Physician profile
Johnathan D Williams
NPI 1245201557
$13,255.03
in general payments reported to CMS, 2019-2025
73 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $1,129 · 2021: $2,631 · 2022: $2,155 · 2023: $2,209 · 2024: $1,746 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,695 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,694.69 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.43 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,115.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,022.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $946.83 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $876.93 | 2021-2025 | |
| Amgen INC. | $871.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $689.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $441.89 | 2019-2025 | Arexvy, Shingrix, Pediarix |
| Sanofi-Aventis U.S. LLC | $411.67 | 2019-2023 | |
| Preventric Diagnostics, INC. | $386.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $374.18 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $328.55 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $316.86 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $274.72 | 2019-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Aytu Biopharma, INC. | $270.79 | 2019-2021 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.